Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Hutchmed (China)
HCM
5
Lantheus
LNTH
US Stock MarketDetailed Quotes
NXTC NextCure
- 0.4651
- +0.0051+1.11%
Trading Apr 28 14:18 ET
13.03MMarket Cap-0.23P/E (TTM)
0.4847High0.4428Low182.99KVolume0.4710Open0.4600Pre Close86.30KTurnover0.87%Turnover RatioLossP/E (Static)28.01MShares1.819952wk High0.20P/B9.79MFloat Cap0.224052wk Low--Dividend TTM21.04MShs Float109.0000Historical High--Div YieldTTM9.11%Amplitude0.2240Historical Low0.4710Avg Price1Lot Size
About NextCure Company
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
Company Profile
SymbolNXTC
Company NameNextCure
Listing DateMay 9, 2019
Issue Price15.00
Founded2015
CEOMr. Michael S. Richman
MarketNASDAQ
Employees43
Fiscal Year Ends12-31
Address9000 Virginia Manor Road,Suite 200
CityBeltsville
ProvinceMaryland
CountryUnited States of America
Zip Code20705
Phone1-240-399-4900
Websitehttp://www.nextcure.com
Company Executives
- Name
- Position
- Salary
- Michael S. Richman
- President, Chief Executive Officer and Director
- 1.04M
- Dr. Timothy Mayer, PhD
- Chief Operating Officer
- --
- Dr. Sol Langermann, PhD
- Chief Scientific Officer
- 681.59K
- Steven P. Cobourn, C.P.A.
- Chief Financial Officer and Principal Accounting Officer
- --
- Kevin G. Shaw
- Senior Vice President and General Counsel
- --
- Dr. Sourav Kundu, PhD
- Senior Vice President, Development and Manufacturing
- --
- Dr. David S. Kabakoff,PhD
- Chairman of the Board
- 93.16K
- Stephen W. Webster
- Independent Director
- 71.66K
- Dr. John G. Houston, PhD
- Independent Director
- 61.66K
- Dr. Ellen G. Feigal, M.D.
- Independent Director
- 61.66K
- Dr. Elaine V. Jones, PhD
- Independent Director
- 67.47K
- Dr. Anne Borgman, M.D.
- Independent Director
- 60.66K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
